ClearPoint Neuro, Inc. — 2016 Form 10-K Summary
Entity and period: The supplied filing identifies the registrant as MRI Interventions, Inc. (ticker MRIC), not ClearPoint Neuro, Inc. It reports the fiscal year ended December 31, 2016, with 2015 comparisons; it is not a standalone fourth-quarter report. Amounts are in U.S. dollars.
Business context
The company develops and sells MRI-guided systems for minimally invasive procedures. Its commercial product, ClearPoint, guides neurological procedures and had U.S. FDA 510(k) clearance and European CE marking. ClearTrace, a cardiac product candidate, remained at preclinical stage; development was suspended in 2015 to focus resources on ClearPoint. The company’s business model emphasizes recurring sales of disposable ClearPoint components.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Total revenue | $5.75 million | $4.59 million |
| Product revenue | $5.61 million | $4.42 million |
| Gross margin on product revenue | 53% | 55% |
| Operating loss | $7.49 million | $8.97 million |
| Net loss | $8.07 million | $8.45 million |
| Cash used in operations | $5.82 million | $8.64 million |
| Cash and cash equivalents at year-end | $3.32 million | $5.41 million |
- Revenue rose 25%; product revenue increased 27%. Disposable sales grew 36% to $4.8 million, mainly from higher procedure volume and a larger installed base. Reusable product sales fell 8% to $831,000.
- Product gross margin declined two percentage points. Management cited sales mix, increased obsolete/expired product charges and higher production labor allocation, partly offset by price and vendor-cost improvements.
- Research and development expense increased 34% to $2.63 million. Selling, general and administrative expense fell 5% to $7.97 million; 2015 included $1.25 million in restructuring charges.
- Year-end current assets were $6.09 million and current liabilities $3.02 million. Total assets were $7.40 million; total liabilities $8.16 million; stockholders’ deficit $756,000.
- Debt principal scheduled at year-end totaled $6.975 million: $2.0 million due in 2018, approximately $1.975 million in 2019 and $3.0 million in 2020. The notes are secured by company assets; accrued interest was $647,500. Carrying values are reduced by unamortized discounts and financing costs.
Material changes and unusual items
- In September 2016, a private placement generated $3.83 million net cash proceeds and converted $1.75 million of notes into equity units. The transaction increased outstanding common shares; the filing reports 3,622,032 shares outstanding at year-end and after the July 2016 1-for-40 reverse split.
- Brainlab debt was restructured in April 2016: principal was reduced through a software license and equity-unit issuance, leaving a $2.0 million senior note due December 2018 at 5.5% interest. The restructuring produced a reported $941,000 accounting gain.
- Debt amendments and conversion features generated a reported $812,000 debt-restructuring loss in 2016. A $1.07 million gain from changes in derivative-liability fair value also affected reported results.
- The company recorded a $459,000 fourth-quarter charge after determining that it would not resume a contemplated public offering within the expected six-month period.
- ClearTrace missed a June 2016 development milestone; Siemens terminated the agreement’s exclusivity provisions. Brainlab’s co-development and distribution agreement expired in April 2016, although it continued to distribute on a purchase-order basis.
Outlook, risks and contingencies
Management expected ClearPoint revenue growth from increased utilization at existing sites and new installations, while anticipating that higher selling and marketing costs could offset expected general and administrative savings. Management nevertheless expected continued operating cash consumption for at least the next 12 months and said additional financing would be necessary. The auditor’s report and management disclosures state that substantial doubt exists about the company’s ability to continue as a going concern; the financial statements contain no adjustments for the outcome of that uncertainty.
- Key risks include ongoing losses, financing availability and dilution, debt repayment/refinancing, slow ClearPoint adoption, reimbursement constraints, customer concentration and reliance on suppliers.
- The filing identifies Emory and UCSF as important ClearPoint customers and reports that Voyager purchased approximately $539,000 of product in 2016. A small number of hospital customers account for a substantial portion of disposable-product revenue.
- ClearPoint disposable products are not separately reimbursed; hospitals generally rely on bundled procedure payments, which may constrain adoption.
- ClearTrace would require further development, testing and regulatory clearance or approval before commercialization; its timing, cost and eventual market prospects are uncertain.
- The company reported no material pending legal proceedings and no material off-balance-sheet arrangements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; auditor attestation of internal controls was not provided.
Important facts for investors to verify
- Confirm the registrant identity and any relationship between MRI Interventions, Inc. and ClearPoint Neuro, Inc.; this filing names MRI Interventions, Inc.
- Review the audited statements and subsequent filings for cash runway, financing raised after year-end, and progress toward resolving the going-concern uncertainty.
- Verify actual debt principal, interest obligations, collateral priority, maturity terms and any subsequent refinancing or conversions.
- Assess whether ClearPoint procedure volumes, installations, disposable sales and gross margins continued to improve, and whether customer concentration changed.
- Check the potential dilution from outstanding warrants and options, and the status of ClearTrace and the terminated Siemens exclusivity.